Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00— vs Q3 2020 Net Income-$9.27M-$9.27MN/M vs Q3 2020 EPS Diluted-$0.12-$0.12N/M vs Q3 2020 Operating Income-$8,517,356N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,359,770N/M ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end